The Latest Cardiac and Vascular News
New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death due to cardiovascular causes or heart failure hospitalization. THE WOODLANDS, Texas, Aug. […]
FIGARO-DKD is the first contemporary cardiorenal outcomes trial with the majority of patients who had an eGFR ≥60 ml/min/1.73m2 to show cardiovascular benefit in chronic kidney disease associated with type 2 diabetes; patients were included in this study if they had UACR levels 30–5000 mg/g1 Additionally, results from FIDELITY, a prespecified […]
The SANTORINI study highlights that low-density lipoprotein cholesterol (LDL-C) levels remain substantially higher than recommended goals in patients who are at high- and very high-risk of cardiovascular events.1 Study data further demonstrate that combination therapies are being under-utilised, with nearly 73% of these patients not receiving combination therapy, despite their […]
– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device – Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and […]
Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full study population Firibastat demonstrated better efficacy compared to ramipril in severe patients with low ejection fraction Firibastat improved blood pressure profile in […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new […]
TORONTO, Aug. 25, 2021 /PRNewswire/ – Baylis Medical announced today the first clinical use of the VersaCross® Large Access Solution in Canada, to perform a Left Atrial Appendage Closure (LAAC) procedure. The new solution includes the world’s first 3-in-1 radiofrequency (RF) wire paired with a seamless shapeable dilator designed to optimize tissue dilation […]
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by […]
Evolut™ FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment DUBLIN, Aug. 24, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut™ FX TAVR system. […]
Malmö, Sweden, August 23, 2021 Preliminary Dan-NICAD II results to be presented at ESC Acarix AB (publ) today announced that the preliminary results of the Dan-NICAD II study will be presented at the ESC congress on 27AUG2021. The Dan-NICAD II trial was initiated in January 2018 to assess non-invasive methods in patients referred to CCTA (Coronary Computed Tomography […]
